Cardiovascular events associated with use of TKIs in CML

A Swedish study tracked vascular complications in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). This class of drug has been shown to significantly prolong life in CML patients but is associated with toxicity over the long term.

A Swedish study tracked vascular complications in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). This class of drug has been shown to significantly prolong life in CML patients but is associated with toxicity over the long term. Tapping nationwide population-based databases, researchers identified nearly 900 CML patients who underwent TKI therapy from 2002–12. For comparison purposes, each patient was paired with five age- and sex-matched controls. Elevated risk for cardiovascular events was observed in the CML group, which tallied 54 arterial events and 20 venous events during a median 4.2 years of followup. Myocardial infarction also was more likely in patients taking nilotinib or dasatinib, compared with those taking imatinib. The researchers suggest that additional study is needed to discover whether the risk for myocardial infarction rises with second-generation TKIs.